
Opinion|Videos|January 29, 2025
Strategies for Managing Neurotoxic AEs With Lorlatinib
Key opinion leaders discuss strategies for managing neurotoxicity with lorlatinib and other ALK inhibitors, including monitoring adverse events and balancing symptom management with treatment efficacy.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Can you discuss your strategies for managing neurotoxicity?
- How are you monitoring these AEs?
- How do you balance symptom management with maintaining treatment efficacy?
Advertisement
Related to this article

Dr. Andrew Pecora on leading the first IV oncolytic virus trial, building a top-50 cancer center, and using AI to fix the cost of cancer care.

In the phase 2 EVITA trial, vitamin C did not slow clonal growth but was linked to fewer serious adverse events and longer exploratory survival.

In observation of National PA Week, Moffitt PA Mark Honor discusses the expansion of APPs and key collaboration strategies for oncology nurses.

Beth Faiman details the new IMS/IMWG consensus definition of cure for multiple myeloma, requiring 5 years of treatment-free remission.

Oncology clinicians gathered to review relapsed CLL care options, CAR T-cell trial updates, and advanced practice provider roles.

At ASTRO 2026, Suresh Rana details how AI-driven contouring accelerates care timelines, requiring rigorous team monitoring and early nursing input.

At ASTRO 2026, Dr. Erica Braschi Jordan details toxicity tracking, physical therapy referral, and quality of life in proton regional nodal irradiation.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Grants Accelerated Approval to Dostarlimab in dMMR Rectal Cancer
2
How AI Could Ease the Cost Crisis in Cancer Care
3
Anktiva Plus BCG: 84% of Responders Cystectomy-Free at 3 Years
4
Automated Breast Ultrasound Tied to Fewer False-Positives in Dense Breasts
5

